Pharmaceuticals Malaysia

Malaysia Immunoglobulin Therapy Market Analysis, 2024–2034

Malaysia Immunoglobulin Therapy Market Industry Trends and Forecast to 2034: Segmented by (Route, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Malaysia · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $20.9 Mn Estimated value
Estimate 2025 $22.5 Mn 0.1% of the global market
Projected 2034 $42.8 Mn 90.1% Adds $20.3 Mn over 9 forecast years
CAGR 2025–2034 7.4% Faster than 39% of 180 Pharmaceuticals markets here
Key players 5
  • Malaysia is 0.14% of the global market.
  • In APAC, the largest is China at $1.44 Bn.
  • Fastest growing: India at 10.4% a year.
  • Malaysia ranks 8th of 10 by size in APAC.

Market size projection

Malaysia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$20.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Immunoglobulin Therapy Market market size by year, Malaysia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $20.9 Mn — —
2025 (base) $22.5 Mn +$1.5 Mn —
2026 (forecast) $24.2 Mn +$1.7 Mn +7.4%
2027 (forecast) $25.9 Mn +$1.8 Mn +15.3%
2028 (forecast) $27.9 Mn +$1.9 Mn +23.9%
2029 (forecast) $29.9 Mn +$2.1 Mn +33.1%
2030 (forecast) $32.1 Mn +$2.2 Mn +42.9%
2031 (forecast) $34.5 Mn +$2.4 Mn +53.5%
2032 (forecast) $37.1 Mn +$2.6 Mn +64.8%
2033 (forecast) $39.8 Mn +$2.7 Mn +77%
2034 (forecast) $42.8 Mn +$2.9 Mn +90.1%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $16.03 Bn
  2. North America $8.46 Bn
  3. US $6.57 Bn
  4. Europe $3.23 Bn
  5. APAC $3.19 Bn
  6. China $1.44 Bn
  7. Canada $1.32 Bn
  8. Japan $1.15 Bn
  9. Latin America $774.1 Mn
  10. Germany $577.4 Mn
  11. Middle East $566.6 Mn
  12. UK $429.5 Mn
  13. Italy $410.4 Mn
  14. France $405.0 Mn
  15. Brazil $371.4 Mn
  16. Ecuador $357.8 Mn
  17. Spain $309.7 Mn
  18. India $329.6 Mn
  19. Mexico $278.2 Mn
  20. Saudi Arabia $269.9 Mn
  21. Africa $231.4 Mn
  22. Australia $212.1 Mn
  23. Russia $147.6 Mn
  24. New Zealand $147.1 Mn
  25. South Africa $106.9 Mn
  26. UAE $85.4 Mn
  27. Egypt $42.1 Mn
  28. Philippines $34.0 Mn
  29. Hong Kong $25.9 Mn
  30. Malaysia (this report) $22.5 Mn
  31. Singapore $19.4 Mn
  32. Thailand $17.4 Mn
  33. Kenya $11.7 Mn

The Malaysia Immunoglobulin Therapy Market Analysis Executive Summary

Immunoglobulin therapy gives antibodies from donated blood to treat immune deficiencies and some nerve and blood diseases.

Key segments of the immunoglobulin Therapy market include route (Intravenous and Subcutaneous) and indication (Primary Immunodeficiency, CIDP and Immune Thrombocytopenia).

Malaysia Immunoglobulin Therapy Market Dynamics

Market Growth Drivers

More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the immunoglobulin Therapy market. Biosimilars are widening access.

Opportunity

New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the immunoglobulin Therapy market room to grow.

Market Restraints

High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the immunoglobulin Therapy market.

Competitive Landscape for Immunoglobulin Therapy Market in Malaysia

The immunoglobulin Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Immunoglobulin Therapy Market in Malaysia

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for immunoglobulin Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Malaysia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Immunoglobulin Therapy right now, from free public sources.

Clinical trials

32 active trials in Malaysia

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. AstraZeneca 70 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Regeneron Pharmaceuticals 48 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Sichuan Baili Pharmaceutical Co., Ltd. 38 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Johnson & Johnson 28 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Novartis AG 20 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 769 papers since 2021 (worldwide)

  1. Immunoglobulins and Efgartigimod reduce neuronal activity in primary rat cortical neuron cultures. Frontiers in cellular neuroscience, 2026
  2. Septic Arthritis From Haemophilus influenzae in Adults: A Report of 2 Cases and Proposed Diagnostic Algorithm. JBJS case connector, 2026
  3. Intracranial hemorrhage in a patient with Guillain-Barré syndrome following intravenous immunoglobulin therapy: A rare complication. Journal of family medicine and primary care, 2026
  4. Beyond the liver: Hepatitis E virus-associated Guillain-Barré syndrome with respiratory failure in an adolescent, a case report. Journal of the National Medical Association, 2026
  5. Patient Preferences for Self-Administered Subcutaneous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy. Neurology and therapy, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Immunoglobulin Therapy in context

Malaysia compared

  • Health spending per person: 450 US$ per person (2023). World: 1,317 US$ per person (2023). 6th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.34 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 6th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 8.0% of people (2025). World: 10.4% of people (2025). 8th highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How many clinical trials on Immunoglobulin Therapy are running in Malaysia?
32 studies are recruiting, active or about to start in Malaysia.[4]
How much research is published on Immunoglobulin Therapy?
PubMed lists 769 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Malaysia. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Immunoglobulin Therapy in Malaysia? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches… Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Malaysia

See all
Same topic, other categories

Related on biologics and biosimilars

See the topic